Xbrane Financial Statements From 2010 to 2025
| XBRANE Stock | SEK 0.15 0.01 6.25% |
Check Xbrane Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xbrane Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Xbrane financial statements analysis is a perfect complement when working with Xbrane Biopharma Valuation or Volatility modules.
Xbrane |
Xbrane Biopharma AB Company Shares Owned By Insiders Analysis
Xbrane Biopharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Xbrane Biopharma Shares Owned By Insiders | 35.23 % |
Most of Xbrane Biopharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xbrane Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 35.23% of Xbrane Biopharma AB are shares owned by insiders. This is 132.08% higher than that of the Healthcare sector and 193.83% higher than that of the Drug Manufacturers - Specialty & Generic industry. The shares owned by insiders for all Sweden stocks is notably lower than that of the firm.
Xbrane Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Xbrane Biopharma's current stock value. Our valuation model uses many indicators to compare Xbrane Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xbrane Biopharma competition to find correlations between indicators driving Xbrane Biopharma's intrinsic value. More Info.Xbrane Biopharma AB is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Xbrane Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Xbrane Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Xbrane Biopharma Financial Statements
Xbrane Biopharma stakeholders use historical fundamental indicators, such as Xbrane Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Xbrane Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Xbrane Biopharma's assets and liabilities are reflected in the revenues and expenses on Xbrane Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Xbrane Biopharma AB. Please read more on our technical analysis and fundamental analysis pages.
Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 35 people.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Xbrane Stock
Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.